- Home
- ADV vs AUPH Comparison
ADV vs AUPH Comparison
Compare ADV & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADV | AUPH |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | Canada |
| Employees | 69000 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.6M | 1.6B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | ADV | AUPH |
|---|---|---|
| Price | $0.73 | $13.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $1.83 | ★ $17.25 |
| AVG Volume (30 Days) | 778.0K | ★ 903.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.35 |
| Revenue Next Year | $1.22 | $15.66 |
| P/E Ratio | ★ N/A | $6.95 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $0.49 | $6.83 |
| 52 Week High | $2.11 | $16.54 |
Technical Indicators
Market Signals| Indicator | ADV | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 41.68 |
| Support Level | $0.51 | $13.52 |
| Resistance Level | $0.97 | $15.23 |
| Average True Range (ATR) | 0.08 | 0.57 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 71.03 | 24.42 |
Price Performance
Historical ComparisonAbout ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.